アジア太平洋地域のポイントオブケア結核および薬剤耐性結核検査の市場規模は2023年に25億3000万ドルと推定され、2024年から2030年にかけて6.6%のCAGRで成長すると予想されます。この成長を促す要因には、この地域の結核負荷の高さ、診断における技術の進歩、支援的な規制の枠組み、政府および国際的な取り組みの強化があります。WHOは、アジア太平洋地域、特に世界人口の約25.0%が住み、世界の結核症例の45.0%以上が負担する東南アジア (SEA) 地域における結核の大きな負担を強調しています。2022年、この地域では480万人以上の新規結核患者と60万人以上の死亡者を記録し、世界の結核死亡率の半分以上を占めています。この高い発生率と死亡率に対応して、診断能力の向上と効果的な疾病管理への注目が高まっていることが、市場の拡大を後押ししています。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Asia Pacific
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test
2.2.2. End Use
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High TB Burden
3.2.1.2. Increased Awareness and Government Initiatives
3.2.1.3. Improving Healthcare Infrastructure
3.2.1.4. Technological Advancements
3.2.2. Market restraint analysis
3.2.2.1. High Cost of Advanced Diagnostic Tests
3.2.2.2. Regulatory and Approval Challenges
3.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Estimates & Trend Analysis
4.1. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Dashboard
4.2. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
4.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market by Test, Revenue
4.4. Molecular Diagnostics
4.4.1. Molecular Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Immunoassays
4.5.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Culture-based Tests
4.6.1. Culture-based Tests market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Serological Tests
4.7.1. Serological Tests market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Estimates & Trend Analysis
5.1. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Dashboard
5.2. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
5.3. Asia Pacific PoC TB and Drug-Resistant TB Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Clinics and Hospitals
5.4.1. Clinics and Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Diagnostic Laboratories
5.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Regional Estimates & Trend Analysis by Test, and End Use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. Asia Pacific
6.3.1. Japan
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. China
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. India
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Australia
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework/ reimbursement structure
6.3.4.3. Competitive scenario
6.3.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Southeast Asia
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework/ reimbursement structure
6.3.5.3. Competitive scenario
6.3.5.4. Southeast Asia market estimates and forecasts 2018 to 2030 (USD Million)
6.3.6. Rest of APAC
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework/ reimbursement structure
6.3.6.3. Competitive scenario
6.3.6.4. Rest of APAC market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key company market share analysis, 2023
7.2.3. Cepheid (Danaher Corporation)
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Molbio Diagnostics
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Abbott Laboratories
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. BD (Becton, Dickinson and Company)
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Roche Diagnostics
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Qiagen
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Lucira Health
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. BioMérieux
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Thermo Fisher Scientific
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Fujifilm (Fujifilm Healthcare)
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. MedMira
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. SD Biosensor
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Trivitron Healthcare
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
List of Tables
Table 1 List Of Abbreviation
Table 2 Asia Pacific PoC TB and Drug-Resistant TB Testing Market, By Region, 2018 - 2030 (USD Million)
Table 3 Asia Pacific PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 4 Asia Pacific PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 5 Japan PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 6 Japan PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 7 China PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 8 China PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 9 India PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 10 India PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 11 Australia PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 12 Australia PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 13 Southeast Asia PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 14 Southeast Asia PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 15 Rest of APAC PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 16 Rest of APAC PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Asia Pacific
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Market Outlook
Fig. 14 Asia Pacific PoC TB and Drug-Resistant TB Testing Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Asia Pacific PoC TB and Drug-Resistant TB Testing Market Driver Impact
Fig. 18 Asia Pacific PoC TB and Drug-Resistant TB Testing Market Restraint Impact
Fig. 19 Asia Pacific PoC TB and Drug-Resistant TB Testing Market Strategic Initiatives Analysis
Fig. 20 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
Fig. 21 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: Test Outlook And Key Takeaways
Fig. 22 Molecular Diagnostics market estimates and forecast, 2018 - 2030
Fig. 23 Immunoassays market estimates and forecast, 2018 - 2030
Fig. 24 Culture-based Tests market estimates and forecast, 2018 - 2030
Fig. 25 Serological Tests market estimates and forecast, 2018 - 2030
Fig. 26 Others market estimates and forecast, 2018 - 2030
Fig. 27 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
Fig. 28 Asia Pacific PoC TB and Drug-Resistant TB Testing Market: End Use Outlook And Key Takeaways
Fig. 29 Clinics and Hospitals market estimates and forecast, 2018 - 2030
Fig. 30 Diagnostic Laboratories market estimates and forecast, 2018 - 2030
Fig. 31 Other market estimates and forecast, 2018 - 2030
Fig. 32 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Japan key country dynamics
Fig. 34 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 China key country dynamics
Fig. 36 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 India key country dynamics
Fig. 38 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Australia key country dynamics
Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Southeast Asia key country dynamics
Fig. 42 Southeast Asia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Rest of APAC key country dynamics
Fig. 44 Rest of APAC market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Market share of key market players- PoC TB and Drug-Resistant TB Testing market
